{
  "ticker": "ARGX",
  "name": "argenx SE",
  "_metadata": {
    "version": "2.1",
    "ticker": "ARGX",
    "company_name": "argenx SE",
    "data_source": "argx_corporate_2026",
    "extraction_date": "2026-02-11",
    "sources": [
      {
        "id": "argx_jpm_2026_slides",
        "type": "corporate_presentation",
        "title": "argenx 2026 JPM Healthcare Conference Corporate Presentation",
        "date": "2026-01-12",
        "url": "https://argenx.com/content/dam/argenx-corp/investors/events-presentations/2026_JPM_Slides_argenx_2026_Corp_Presentation.pdf",
        "slides": 26,
        "verified": true
      }
    ]
  },
  "company": {
    "name": "argenx SE",
    "ticker": "ARGX",
    "exchange": "Euronext & Nasdaq",
    "headquarters": null,
    "website": null,
    "one_liner": "argenx is an immunology company pioneering FcRn-targeting therapies led by VYVGART (efgartigimod), with a broad pipeline of antibody-based medicines across autoimmune diseases in neurology and rheumatology.",
    "market_cap": "$35B",
    "strategic_vision": {
      "name": "Vision 2030",
      "goals": [
        "Treat 50,000 patients globally",
        "Secure 10 labeled indications across all approved medicines",
        "Advance 5 pipeline candidates into Phase 3 by 2030"
      ],
      "2026_priorities": [
        "4 registrational readouts (Ocular MG, Myositis, ITP, MMN)",
        "Seronegative gMG launch if approved by end 2026",
        "3 new molecules to enter Phase 1 (10 clinical-stage by year-end)",
        "VYVGART SC autoinjector preparation for 2027 launch",
        "ADAPT-Forward combination study (efgartigimod + empasiprubart in gMG)"
      ],
      "source": {
        "id": "argx_jpm_jan2026",
        "slide": null,
        "verified": false
      }
    },
    "management_changes": {
      "incoming_ceo": "Karen Massey (current COO \u2192 CEO, subject to AGM approval May 6, 2026)",
      "outgoing_ceo": "Tim Van Hauwermeiren (CEO \u2192 non-Executive Director & Chairman)",
      "new_cco": "Sandrine Piret-G\u00e9rard (Chief Commercialization Officer, ex-Gilead US commercial lead)",
      "retiring": "Peter Verhaeghe (retiring from Board)",
      "source": {
        "id": "argx_jpm_jan2026",
        "slide": null,
        "verified": true
      }
    },
    "tam_detail": {
      "mg_us_addressable_at_launch": "17K patients",
      "mg_seronegative_expansion": "+11K patients",
      "mg_ocular_expansion": "+7K patients",
      "mg_biologics_share_growth": "+25K patients",
      "mg_total_addressable_2030": "60K patients",
      "cidp_addressable_at_launch": "12K patients",
      "cidp_total_treated": "24K patients",
      "cidp_total_diagnosed": "42K patients",
      "myositis_us_prevalence": "70K (DM 40K, IMNM 20K, PM 10K)",
      "sjogrens_us_prevalence": "330K total, 100K moderate-to-severe",
      "mmn_patients_key_markets": "12K patients",
      "mmn_market_current": "$750-800M",
      "mmn_market_2030": "$1B+",
      "source": {
        "id": "argx_jpm_2026_slides",
        "slides": [
          12,
          13,
          14,
          18
        ],
        "verified": true
      }
    }
  },
  "investment_thesis_summary": {
    "core_thesis": "argenx is building a dominant, multi-asset immunology franchise anchored by VYVGART, which achieved $4.2B in 2025 product net sales (+90% YoY) and first-year operating profitability. The company has 10 ongoing registrational studies with 6 Phase 3 readouts over the next 24 months, positioning it for significant label expansion and pipeline diversification through Vision 2030.",
    "key_value_drivers": [
      "VYVGART product net sales of $4.2B in 2025 with 90% YoY growth and first-year operating profitability",
      "6 registrational Phase 3 readouts over next 24 months across efgartigimod and empasiprubart",
      "Vision 2030 targets: 50K patients on treatment, 10 labeled indications, 5 new molecules in Phase 3"
    ]
  },
  "investment_analysis": {
    "bull_case": [
      "VYVGART is #1 prescribed biologic in MG, driving 60% growth in overall MG biologics share, with expanding prescriber base (>4,700 US prescribers, 20% YoY increase)",
      "MG total addressable market expected to grow from 17K at launch to 60K patients in the US by 2030 through seronegative, ocular, and biologics share expansion",
      "Empasiprubart Phase 3 readout in MMN in 4Q 2026 targets a $750-800M market expected to grow beyond $1B by 2030 with zero targeted treatments currently available",
      "Diversified FcRn franchise with 3 clinical-stage FcRn molecules (VYVGART, ARGX-213 Phase 3 ready, ARGX-124 Phase 1) providing lifecycle protection",
      "Deep pipeline with 25 active IIP programs, 10 clinical-stage molecules, and 3 new Phase 1 molecules entering clinic in 2026",
      "70% of new MG patients coming directly from orals, indicating earlier line treatment adoption and market expansion",
      "CIDP achieved blockbuster status as of 3Q 2025 with clear path to expansion (12K addressable at launch, 42K total diagnosed)"
    ],
    "bear_case": [
      "UplighTED Phase 3 TED trials discontinued for futility (Dec 15, 2025) \u2014 IDMC recommended stopping after interim analysis showed treatment unlikely to meet proptosis primary endpoint at Week 24. Removes ~$550M peak sales opportunity. Stock fell >5% on announcement.",
      "Multiple Phase 3 trials carry execution risk \u2014 Ocular MG uses novel MGII primary endpoint, Myositis has heterogeneous disease with TIS composite endpoint, Sjogren's has challenging primary endpoint",
      "ITP trial targets difficult-to-treat patients, potentially limiting broad applicability of results",
      "Empasiprubart MMN Phase 3 (EMPASSION) is a head-to-head trial vs IVIg, a high bar for a registrational study",
      "FcRn class competition may emerge from next-generation molecules from other companies",
      "Expansion into rheumatology (Myositis, Sjogren's) represents new therapeutic areas where no targeted therapies are currently approved, creating regulatory pathway uncertainty"
    ],
    "key_debates": [
      {
        "question": "Can argenx sustain VYVGART revenue growth as the MG market matures and expand successfully into new indications?",
        "bull_view": "MG TAM growing from 17K to 60K, with seronegative label expansion pending, ocular MG Phase 3, and combination approaches with empasiprubart driving further growth",
        "bear_view": "MG growth may plateau as biologics penetration matures; new indications carry Phase 3 execution risk with novel endpoints",
        "what_resolves_it": "Ocular MG Phase 3 readout in 1Q 2026, seronegative MG approval decision by end of 2026, and sequential Phase 3 readouts through 2027"
      },
      {
        "question": "Will empasiprubart succeed in Phase 3 and become a meaningful second franchise?",
        "bull_view": "Phase 2 ARDA data showed sustained grip strength improvement in MMN through 64 weeks in open-label extension; MMN has zero targeted treatments and >$1B market opportunity",
        "bear_view": "EMPASSION is a head-to-head trial vs IVIg which is a high bar; Phase 2 sample sizes were small (N=9-18 per arm)",
        "what_resolves_it": "EMPASSION Phase 3 readout in MMN expected 4Q 2026"
      },
      {
        "question": "Can argenx maintain FcRn leadership long-term against emerging competition?",
        "bull_view": "3 clinical-stage FcRn molecules, autoinjector estimated 2027, partnerships with Elektrofi (small volume delivery) and Unnatural Products (oral peptides) for next-generation delivery",
        "bear_view": "Competition in FcRn class is increasing; patent cliffs may eventually erode exclusivity",
        "what_resolves_it": "ARGX-213 Phase 3 readiness and differentiation data vs efgartigimod (sustained IgG reduction shown in Phase 1); ARGX-124 Phase 1 data"
      }
    ]
  },
  "pipeline_summary": {
    "total_programs": 10,
    "clinical_stage": 10,
    "programs": [
      {
        "asset": "Efgartigimod (VYVGART / VYVGART Hytrulo)",
        "target": "FcRn",
        "stage": "Approved / Phase 3 (multiple indications)",
        "indications": "gMG (AChR+, approved; seronegative pending), Ocular MG, ITP, Myositis, Sjogren's Disease, Graves' Disease",
        "ownership": "Wholly-owned",
        "next_catalyst": "Ocular MG Phase 3 readout \u2014 1Q 2026",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "asset": "Empasiprubart",
        "target": "C2 (complement)",
        "stage": "Phase 3 / PoC",
        "indications": "MMN, CIDP, AMR, Scleroderma, AIE, DGF, ALS, SMA",
        "ownership": null,
        "next_catalyst": "MMN Phase 3 (EMPASSION) readout \u2014 4Q 2026",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "asset": "Adimanebart",
        "target": "MuSK",
        "stage": "Registrational / PoC",
        "indications": "CMS, ALS, SMA",
        "ownership": null,
        "next_catalyst": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "asset": "ARGX-213",
        "target": "FcRn (sustained IgG reduction)",
        "stage": "Phase 3 ready (Registrational)",
        "indications": "15+ potential indications",
        "ownership": null,
        "next_catalyst": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      },
      {
        "asset": "ARGX-121",
        "target": "IgA (IgA sweeping antibody)",
        "stage": "PoC",
        "indications": "IgA Nephropathy, 3+ potential indications",
        "ownership": null,
        "next_catalyst": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "asset": "ARGX-109",
        "target": "IL-6",
        "stage": "PoC",
        "indications": null,
        "ownership": null,
        "next_catalyst": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 23,
          "verified": false
        }
      },
      {
        "asset": "ARGX-118",
        "target": "Galectin-10",
        "stage": "Phase 1",
        "indications": null,
        "ownership": null,
        "next_catalyst": "Phase 1 initiation in 2026",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 22,
          "verified": false
        }
      },
      {
        "asset": "ARGX-124",
        "target": "FcRn",
        "stage": "Phase 1",
        "indications": null,
        "ownership": null,
        "next_catalyst": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      },
      {
        "asset": "ARGX-125",
        "target": "Not disclosed",
        "stage": "Preclinical",
        "indications": null,
        "ownership": null,
        "next_catalyst": "Phase 1 initiation in 2026",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 22,
          "verified": false
        }
      },
      {
        "asset": "Tensegrity (TSP-101)",
        "target": "Fn14",
        "stage": "Phase 1",
        "indications": null,
        "ownership": null,
        "next_catalyst": "Phase 1 in 2026",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 22,
          "verified": false
        }
      }
    ],
    "total_iip_programs": 25,
    "clinical_stage_molecules": "6 currently, target 10 by end 2026",
    "phase_3_molecules": "3 currently (efgartigimod, empasiprubart, adimanebart entering), target 4 by end 2026",
    "registrational_readouts_next_24mo": 6,
    "ind_target": "1 new IND per year"
  },
  "platform": {
    "name": "Antibody Engineering / Innovation Engine",
    "description": "argenx's innovation engine combines pioneering novel biology, pipeline-in-a-product strategy, and best-in-field antibody engineering including proprietary Fc-ABDEG technology. Sourcing from academic research centers, immunology labs, and biopharma companies. 25 active IIP programs spanning neurology, rheumatology, renal, and skin targets with a target of 1 IND per year.",
    "source": {
      "id": "argx_corporate_2026",
      "slide": 22,
      "verified": false
    }
  },
  "financials": {
    "cash_position": null,
    "cash_runway": null,
    "market_cap": "$35B (approx. Feb 2026)",
    "enterprise_value": null,
    "revenue": "$4,151 million (FY 2025 preliminary product net sales, +90% YoY)",
    "revenue_detail": {
      "fy_2025": "$4,151 million",
      "fy_2024": "$2,186 million",
      "yoy_growth": "+90% (ex-FX)",
      "q4_2025": "$1,286 million",
      "q4_2024": "$737 million",
      "q4_yoy_growth": "+74% (ex-FX)",
      "q3_2025": "$1,127 million",
      "q4_vs_q3_growth": "+14% (ex-FX)",
      "first_year_operating_profitability": true
    },
    "source": {
      "id": "argx_jpm_2026_slides",
      "slide": 7,
      "verified": true
    },
    "patients_on_treatment": "~19,000 globally (as of Jan 2026)",
    "first_operating_profitability": "2025 (first year)",
    "analyst_consensus": {
      "ubs_target": "$910 (Dec 2025)",
      "ubs_2026_vyvgart_estimate": "$6.1B",
      "oppenheimer_target": "$1,040",
      "td_cowen_target": "$1,146",
      "piper_sandler_target": "$930",
      "source": {
        "id": "analyst_reports_dec_2025",
        "slide": null,
        "verified": false
      }
    },
    "quarterly_revenue": {
      "Q1_2022": 21,
      "Q2_2022": 75,
      "Q3_2022": 131,
      "Q4_2022": 173,
      "Q1_2023": 218,
      "Q2_2023": 269,
      "Q3_2023": 329,
      "Q4_2023": 374,
      "Q1_2024": 398,
      "Q2_2024": 478,
      "Q3_2024": 573,
      "Q4_2024": 737,
      "Q1_2025": 790,
      "Q2_2025": 949,
      "Q3_2025": 1127,
      "Q4_2025": 1286,
      "unit": "millions_usd",
      "source": {
        "id": "argx_jpm_2026_slides",
        "slide": 7,
        "verified": true
      }
    }
  },
  "catalysts": [
    {
      "asset": "Efgartigimod",
      "event": "Seronegative gMG sBLA \u2014 FDA Priority Review, PDUFA May 10, 2026",
      "timing": "PDUFA: May 10, 2026",
      "importance": "critical",
      "what_to_watch": "FDA accepted sBLA with Priority Review. ADAPT-SERON met primary endpoint (p=0.0068). MG-ADL improvement of 3.35 points at Week 4. If approved, broadest MG label \u2014 adds ~20% of gMG patients (MuSK+, LRP4+, triple seronegative). No approved treatments exist for LRP4+ or triple seronegative patients. Launch expected by end 2026."
    },
    {
      "asset": "Efgartigimod",
      "event": "Ocular MG Phase 3 data readout (ADAPT Oculus)",
      "timing": "1Q 2026",
      "importance": "critical",
      "what_to_watch": "MGII novel primary endpoint result; first and only development program in Ocular MG"
    },
    {
      "asset": "Efgartigimod",
      "event": "Myositis Phase 3 data readout (ALKIVIA)",
      "timing": "3Q 2026",
      "importance": "critical",
      "what_to_watch": "TIS composite primary endpoint in heterogeneous disease; significant improvement in muscle strength shown in Phase 2"
    },
    {
      "asset": "Efgartigimod",
      "event": "ITP Phase 3 data readout (ADVANCE NEXT)",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Cumulative platelet count primary endpoint in difficult-to-treat patients; supported by ADVANCE Phase 3 IV and real world data from Japan"
    },
    {
      "asset": "Empasiprubart",
      "event": "MMN Phase 3 data readout (EMPASSION)",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Head-to-head trial vs IVIg; first targeted treatment in MMN where 60% of patients progress despite current treatment"
    },
    {
      "asset": "Efgartigimod",
      "event": "Seronegative gMG sBLA \u2014 FDA Priority Review, PDUFA May 10, 2026",
      "timing": "PDUFA: May 10, 2026",
      "importance": "critical",
      "what_to_watch": "FDA accepted sBLA with Priority Review. ADAPT-SERON met primary endpoint (p=0.0068). MG-ADL improvement of 3.35 points at Week 4. If approved, broadest MG label \u2014 adds ~20% of gMG patients (MuSK+, LRP4+, triple seronegative). No approved treatments exist for LRP4+ or triple seronegative patients. Launch expected by end 2026."
    },
    {
      "asset": "Efgartigimod",
      "event": "Sjogren's Disease Phase 3 data readout (UNITY)",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Challenging primary endpoint; Phase 2 showed reductions in systemic disease activity; 330K US prevalence, 100K moderate-to-severe"
    },
    {
      "asset": "Empasiprubart",
      "event": "CIDP Phase 3 data readout",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Co-positioning with VYVGART in CIDP; expanding beyond current 12K addressable market toward 42K total diagnosed patients"
    },
    {
      "asset": "VYVGART",
      "event": "Autoinjector launch (partnership with Ypsomed)",
      "timing": "Estimated 2027",
      "importance": "medium",
      "what_to_watch": "Further optimization of patient experience beyond PFS"
    },
    {
      "asset": "Efgartigimod",
      "event": "UplighTED Phase 3 TED \u2014 DISCONTINUED for futility",
      "timing": "Dec 15, 2025 (completed \u2014 FAILED)",
      "importance": "high",
      "what_to_watch": "IDMC recommended stopping after interim futility analysis. Proptosis primary endpoint not met at Week 24. Safety was clean. Removes TED indication from pipeline. Data to be presented at future medical meeting."
    },
    {
      "asset": "Efgartigimod + Empasiprubart",
      "event": "ADAPT-Forward combination study ongoing in AChR+ gMG",
      "timing": "Ongoing (started 2025)",
      "importance": "medium",
      "what_to_watch": "First study exploring efgartigimod-anchored combination with empasiprubart for deeper efficacy in gMG"
    },
    {
      "asset": "Efgartigimod",
      "event": "Graves' disease registrational study initiation",
      "timing": "2026",
      "importance": "medium",
      "what_to_watch": "New indication expanding into thyroid-driven autoimmunity. Separate from discontinued TED program \u2014 Graves' targets the underlying thyroid autoimmunity, not orbital disease."
    },
    {
      "asset": "Adimanebart (ARGX-119)",
      "event": "CMS registrational study initiation",
      "timing": "3Q 2026",
      "importance": "high",
      "what_to_watch": "First-in-class MuSK agonist entering registrational study. Positive PoC data in CMS."
    },
    {
      "asset": "ARGX-121",
      "event": "Phase 2 study in IgA nephropathy (IgAN) initiation",
      "timing": "2026",
      "importance": "medium",
      "what_to_watch": "First-in-class IgA-targeting molecule. Large market (IgAN affects ~130K US patients)."
    },
    {
      "asset": "ARGX-118, ARGX-125, TSP-101",
      "event": "Three new molecules entering Phase 1",
      "timing": "2026",
      "importance": "medium",
      "what_to_watch": "ARGX-118 (Galectin-10, first-in-class), ARGX-125 (first-in-class bispecific), TSP-101 (Fn14, via Tensegrity collaboration with acquisition option). Goal: 10 clinical-stage molecules by end 2026."
    },
    {
      "asset": "Empasiprubart",
      "event": "EMVIGORATE + EMNERGIZE Phase 3 data (CIDP)",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Two CIDP studies. Co-positioning with VYVGART to expand beyond 12K current addressable to 42K total diagnosed."
    },
    {
      "asset": "Empasiprubart",
      "event": "VARVARA Phase 2 DGF decision (52-week efficacy analysis)",
      "timing": "Mid-2026",
      "importance": "medium",
      "what_to_watch": "Delayed graft function in kidney transplant. Decision on further development after full efficacy analysis."
    }
  ],
  "market_cap": "$51B"
}